Lead Product(s) : Telmisartan,Amlodipine,Indapamide
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Bausch Health
Deal Size : Undisclosed
Deal Type : Licensing Agreement
George Medicines, Bausch Health Sign Licensing Agreement for GMRx2 in Canada
Details : Under the terms of the licensing agreement, Bausch Health will hold the exclusive rights to commercialize, GMRx2 in Canada, Mexico etc. It is being evaluated for the treatment of hypertension.
Product Name : GMRx2
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 13, 2025
Lead Product(s) : Telmisartan,Amlodipine,Indapamide
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Bausch Health
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Telmisartan,Amlodipine,Indapamide
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
George Medicines Files NDA with FDA for Triple Combination Therapy for Hypertension
Details : GMRx2 is a triple combination of telmisartan, amlodipine and indapamide, in Phase III development for hypertension and for the prevention of recurrent intracerebral haemorrhage.
Product Name : GMRx2
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 08, 2024
Lead Product(s) : Telmisartan,Amlodipine,Indapamide
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Telmisartan,Amlodipine,Indapamide
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : GMRx2 is a single-pill, multi-mechanism, triple combination of telmisartan, amlodipine and indapamide, in novel and proprietary dosage strengths and is in Phase III development for hypertension and for the prevention of recurrent intracerebral haemorrhag...
Product Name : GMRx2
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 07, 2023
Lead Product(s) : Telmisartan,Amlodipine,Indapamide
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Telmisartan,Amlodipine,Indapamide
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : GMRx2 is George Medicine’s most advanced candidate in late-stage development. A single-pill triple combination, it contains low doses of the commonly used hypertension medications telmisartan, amlodipine and indapamide.
Product Name : GMRx2
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 09, 2022
Lead Product(s) : Telmisartan,Amlodipine,Indapamide
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rexmyelocel-T
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : $55.9 million
Deal Type : Financing
Ixaka (Formerly Rexgenero) Launches as an Integrated Cell and Gene Therapy Company
Details : The new business will continue to develop Ixaka’s proprietary technologies – concentrated multi-cell therapies and targeted nanoparticle therapeutics. REX-001, Ixaka’s lead MCT product, is an autologous cell-based product in clinical development fo...
Product Name : REX-001
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
January 18, 2021
Lead Product(s) : Rexmyelocel-T
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : $55.9 million
Deal Type : Financing
Lead Product(s) : Telmisartan,Amlodipine,Indapamide
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : GMRx2 is a single pill triple combination in novel and proprietary dosage strengths containing telmisartan, amlodipine and indapamide, targeted for first line therapy to control hypertension.
Product Name : GMRx2
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 07, 2021
Lead Product(s) : Telmisartan,Amlodipine,Indapamide
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ticagrelor,Aspirin
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Phase III THALES trial showed aspirin plus BRILINTA 90mg used twice daily for 30 days, resulted in a statistically significant and clinically meaningful reduction in the risk of the primary composite endpoint of stroke and death, compared to aspirin alon...
Product Name : Brilinta
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 07, 2020
Lead Product(s) : Ticagrelor,Aspirin
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ticagrelor,Aspirin
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
AZ Unveils Detailed Data from THALES Trial
Details : The Phase III THALES results shows that a combination of twice daily Brilinta (ticagrelor) and daily aspirin reduced the rate of stroke and death by 17% after 30 days compared to aspirin alone in patients with acute ischemic stroke or transient ischemic ...
Product Name : Brilinta
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 16, 2020
Lead Product(s) : Ticagrelor,Aspirin
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dapagliflozin
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
FARXIGA Granted FDA Priority Review For Patients With Heart Failure With Reduced Ejection Fraction
Details : The sNDA was based on results from the landmark Phase III DAPA-HF trial, which showed FARXIGA reduced the incidence of the composite outcome of CV death or the worsening of HF versus placebo.
Product Name : Forxiga
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 01, 2020
Lead Product(s) : Dapagliflozin
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ticagrelor,Aspirin
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
BRILINTA Met Primary Endpoint in the Phase III THALES Trial in Stroke
Details : BRILINTA reduced the risk of the composite of stroke and death after an acute ischemic stroke or transient ischemic attack.
Product Name : Brilinta
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 27, 2020
Lead Product(s) : Ticagrelor,Aspirin
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable